Hanover Portfolio Acquisitions, Inc. 6320 Canoga Avenue, 15th Floor

Woodland Hills, CA 91367 Phone: (800) 701-1223

hvpa@hamptongrowth.com www.hanoverpai.com

Company Overview

Hanover Portfolio Acquisitions, Inc., (OTCQB:HVPA) “Hanover” or the "Company", is an intellectual property investment and monetization firm focused on creating shareholder value through joint ventures, licensing and direct investments in innovation. Hanover specializes in the commercialization of healthcare, energy, consumer electronics, and internet/mobile related technologies. The Company commercializes intellectual property in the United States and territories including Brazil, Russia, India, China and the European Union. Hanover’s goal is to maximize the value of intellectual property by turning patents into royalty-generating assets and shortening the time to market for innovative technologies and products in new markets.

Company Statistics (as of 2/1/2013) Ticker: HVPA State of Incorporation: Delaware Share Price: $0.185 52 Week Range: $0.06 - $0.51 3 Avg. Month Trading Volume: 67,053 Shares Outstanding: 52.7 M Market Capitalization: $9.7 M Information compiled from OTCMarkets www.hanoverpai.com

Recent News

• IP Resources Arranges Licensing Deal for New Stem Cell Skin Care Product on Forbes List of Top 10 Fashion and Beauty Startups for 2012

• Hanover Portfolio Acquisitions Signs Letter of Intent to Acquire Pain Management Medical Device Company Addressing Estimated $2.5 Billion U.S. Market

Experienced Management Team Marketing: Management has a record of branding products and companies, including Microsoft “Windows” and Neutrogena. IP Management: Management has experience in formulating and implementing intellectual property strategies and acquisitions. Licensing: Management has experience in using licensing agreements to increase revenues in multiple industries.

Investment Catalysts The Definition of Intellectual Property From a commercial perspective: those rights that form a legal basis for providing a business with a sustainable competitive advantage. $237 Billion Market Hanover addresses the market for worldwide royalty and licensing fees estimated at $237 billion in 2011 according to the International Monetary Fund (IMF). Intangible Assets Drive Market Value Intangible assets currently account for approximately 80% of the market capitalization of the S&P 500 according to Ocean Tomo, a leading intellectual property merchant bank. Intangibles accounted for approximately 17% of the market capitalization of the S&P 500 in 1975. This trend demonstrates the increasing importance of intangible assets in maintaining a competitive advantage and generating revenue for companies. Intellectual Property is an Emerging Asset Class According to the World Intellectual Property Organization (WIPO), only 3% of patents become royalty-generating assets. Furthermore, of those royalty-generating patents, the majority are mismanaged, causing royalties to be under collected by 25% or more. This issue clearly demonstrates the importance of monetizing and effectively managing intellectual property. The Company is positioned to become a market leader in direct investments in innovation and helping companies to maximize shareholder value through the monetization of their intellectual property. China's Acceptance of Intellectual Property It was reported that over 391,000 patent applications were filed at the State Intellectual Property Office (SIPO) in China in 2011. Furthermore, licensing agreements have grown from 118 in 2007 to over 10,000 annually since 2008. This indicates that China is in line to become the second largest patent market worldwide, changing the traditional perception that China does not respect intellectual property rights.

Experienced Professionals with Expertise Across Multiple Disciplines and Industries Hanover’s management team is comprised of individuals with expertise across multiple disciplines, including business development, distribution, marketing, international licensing, mergers and acquisitions. Management has expertise in managing early stage companies and commercializing technologies.

SELECT MANAGEMENT:

Alan Collier: Chief Executive Officer Mr. Collier has over twenty years of experience in corporate finance, telecommunications, mobile technologies, and consumer products. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance, and entertainment industries.

William Scigliano: Chief IP Officer Mr. Scigliano was formerly CEO of IQ Biometrix, Inc. (NYSE), a provider of digital face technologies, where he drove the endorsement and licensing of the company's technology by thousands of agencies worldwide and led the company's subsequent acquisition. He currently serves as executive advisor to the U.S. National Association of Attorneys General in Washington, D.C.

Don Calabria: Chief Operating Officer Mr. Calabria has over seventeen years of leadership and experience in national business operations. He was formerly VP of Operations for TrinTel Communications, the largest privately held infrastructure company in the wireless telecommunications industry.

Rowland Hanson: Managing Director Mr. Hanson was formerly Vice President of Corporate Communications at Microsoft, where he created and executed the company's highly acclaimed branding strategy for products including Microsoft "Windows®."

Alex Lightman: Vice President of Technology Mr. Lightman has made significant contributions to the adoption of IPv6 and served as CTO of the United Nations‘ Intergovernmental Renewable Energy Organization, and has authored several books on technology and society.

Bruce Garfield: VP of Sales & Marketing Mr. Garfield has over forty years of experience in the consumer products sector. He has led five separate companies to sales in excess of $20 million in less than three years, including VTech Communications, a seller of cordless phones, whose sales were in excess of $400 million with a 35% market share.

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are forward looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. A fuller discussion of the Company’s risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission.

Products & Markets

Select Licensed Technologies Hanover has entered into licensing/commercialization agreements with American CryoStem Corporation, CPaiR, Inc., and Xtreme Electronics Systems, Inc.

American CryoStem Corporation - Adipose-Derived Adult Stem Cells American CryoStem Corporation has created and patented a commercial platform to collect, process and cryopreserve Adipose Tissue (fat) into the stromal vascular faction (SVF) which contains Adipose-Derived Stem Cells (ADSCs) and other Regenerative Cells, such as white blood cells, endothelial cells, smooth muscle cells, pericytes, fibroblasts, and pre-adipocytes.

CPaiR, Inc. - An Innovative Medical Device Company CPaiR has developed a patented device that guides rescuers through the correct CPR procedure during an emergency. The CPaiR "Pillow" is anatomically designed to align the victim's head in the correct position for an open airway. The device also provides clear and concise voice prompts that provide rescuers with the accurate timing of chest compressions. The CPaiR facemask allows rescuers to perform mouth-to-mouth resuscitation without transmitting bacteria/infections. In addition, the facemask features a magnification window that provides rescuers with an easy visual assessment of the airway for mouth color and the presence of secretions or foreign objects.

Xtreme Electronics Systems, Inc. Xtreme Electronics Systems (XES) is an innovative, commercial-grade glassless 3D developer. XES' technology was developed for medical applications and provides surgeons with glassless 3D theatre for diagnostic and surgical procedures. In one of many published medical studies, “The Impact of 2D versus 3D Quantization of Tumor Bulk…,” reveals 3D to be far more accurate. “3D assessments of volume versus 2D methods of tumor assessment would have changed the treatment response category in 23% of the cases. 2D volume method of calculating tumor volume overestimated the tumor size.” XES' 16 medical related patents provide for 3D medical education and surgeries, as well as numerous consumer applications.